Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells

Haematologica

Volumn 90, Issue 11, 2005, Pages 1577-1578

  Arseni, Natalia ^a,b   Ahmed, Farid ^a,b   Hiddemann, Wolfgang ^a,b   Buske, Christian ^a,b   Feuring Buske, Michaela ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AML; FLT 3; Leukemic stem cell; Receptor tyrosine kinase inhibitor

Indexed keywords

SEMAXANIB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DEMOGRAPHY; DRUG EFFECT; GENE MUTATION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; STATISTICAL SIGNIFICANCE; STEM CELL;

ADULT; AGED; CELLS, CULTURED; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLES; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 27844534005     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
2. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-8.
3. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STATS is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002;30:262-71.
4. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763-7.
5. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
6. Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003;101:1494-504.
7. Eaves C, Miller C, Cashman J, Conneally E, Petzer A, Zandstra P, et al. Hematopoietic stem cells: inferences from in vivo assays. Stem Cells 1997;15 Suppl 1:1-5.
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
9. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9.
10. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002;62:1730-6.